The Patent Finder
FP

Flagship Pioneering, Inc.

First filing 2015
OverviewNotableFeesChangesFamiliesPatent listSources & methods

32 patents currently held

38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2037. from the record

Of the 38 now held by other companies, 28 were conveyed to Flagship Pioneering Innovations VI LLC in the filing they arrived in, and 10 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2037
Next term end
25
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 4, 2027
    The maintenance fee for Methods and Related Compositions for Manufacturing Food and Feed (US 11,690,387) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
  • 1 fee due Apr 29, 2027
    The maintenance fee for Methods and Compositions for Treating Cancer Using P2RX2 Inhibitors (US 10,457,740) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
  • 1 fee due May 14, 2027
    The maintenance fee for Active Agents and Methods of Their Use for the Treatment of Metabolic Disorders and Nonalcoholic Fatty Liver Disease (US 11,813,272) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Methods of Altering a Target Nucleotide Sequence with an RNA-Guided Nuclease and a Single Guide RNA (US 11,859,219) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Oct 9, 2027
    The maintenance fee for Compositions and Methods for Cell Delivery (US 11,951,154) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
  • 1 fee due Nov 7, 2027
    The maintenance fee for Compositions and Related Methods for Modulating Endosymbionts (US 11,974,574) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The 5 largest of its 25 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,624,065Methods and Compositions for Modulating Gene Expression
In force
 · Medium confidence
In forceMedium confidence
US 11,382,950Compositions and Methods for Cell Delivery
In force
 · High confidence
In forceHigh confidence
US 11,951,154Compositions and Methods for Cell Delivery
In force
 · High confidence
In forceHigh confidence
US 12,171,801Compositions and Related Methods for Controlling Vector-Borne Diseases
In force
 · Medium confidence
In forceMedium confidence
US 11,859,219Methods of Altering a Target Nucleotide Sequence with an RNA-Guided Nuclease and a Single Guide RNA
In force
 · High confidence
In forceHigh confidence
US 12,018,049Compositions and Related Methods for Controlling Vector-Borne Diseases
In force
 · High confidence
In forceHigh confidence
US 12,209,246Methods of Genetically Altering a Whole Plant Seed
In force
 · High confidence
In forceHigh confidence
US 10,457,740Methods and Compositions for Treating Cancer Using P2RX2 Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,312,955Methods and Compositions for Modulating Gene Expression
In force
 · Medium confidence
In forceMedium confidence
US 12,509,683Methods and Compositions for Modulating Gene Expression
In force
 · Low confidence
In forceLow confidence
10 of 32 patents shown.
Pro members see all 32.
Pro members: see all 32 patents
Also on record, not counted in the 32: 38 patents in force now held by others · 6 patents ended · 157 applications pending · 63 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited